Industry
Biotechnology
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Loading...
Open
1.03
Mkt cap
46M
Volume
56K
High
1.39
P/E Ratio
-5.29
52-wk high
3.23
Low
1.03
Div yield
N/A
52-wk low
0.63
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
September 30, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
September 27, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 6:20 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 4:39 pm
Portfolio Pulse from Benzinga Insights
September 27, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Insights
March 26, 2024 | 9:32 pm
Portfolio Pulse from Benzinga Insights
March 08, 2024 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.